top of page

Dr. Rivka Riven Kreitman,

SVP, Head of Scientific Evaluation and Alliance Management,

Global R&D at Teva Pharmaceuticals

Improving the World

Responsible globally at Teva Pharmaceuticals for leading the search for new products, scientific evaluation of all opportunities, and managing collaboration with partners on early stage assets and technologies. 


Executive Board member of the Philadelphia-Israel Chamber of Commerce and co-chair of its science and technology committee.


Research & Development

Rivka Riven Kreitman heads Scientific Evaluation and Alliance Management (SEAM) in Global Research & Development at Teva Pharmaceuticals. Her SEAM team plays a critical role in ensuring that Teva establishes effective partnerships in support of the company's mission of building a robust and competitive pipeline. This includes identifying early stage opportunities (pre-Proof of Concept), scientific assessment, coordination of R&D due diligence, and ongoing alliance management with potential and actual partners. 

Prior to joining Teva R&D, Dr. Kreitman served as Head of Global Strategic Marketing, Biologics and Cell Therapy, in the Teva Specialty Medicines group. She has over 20 years of experience at Teva encompassing the full discovery and development lifecycle. She also brings to R&D broad commercial and market-facing expertize.


Her previous positions have included business development, pharmacology studies management, project leadership, management of global clinical operations, and leadership of Global Innovative R&D. She holds a Ph.D. from the Weizmann Institute of Science, Israel, in Biochemistry. She undertook postdoctoral work on Molecular Biology at Princeton University in the United States.



Teva Buying Allergan for $40 Billion


Teva Announces Positive Results on Tardive Dyskinesia Drug


Teva develops, produces, and markets affordable generic drugs, innovative and specialty pharmaceuticals, and active pharmaceutical ingredients. The company’s line of generic and specialty treatments is backed by global development and manufacturing capabilities, ensuring high quality and accessibility to medicines while reducing costs. 


Established in Jerusalem in 1901, the company known today as Teva started out as a small wholesale drug business that distributed imported medications. The business was named S.L.E after its founders Chaim Salomon, Moshe Levin, and Yitschak Elstein. Together, Salomon, Levin, and Elstein opened a small pharmaceutical plant called Assia ("Doctor" in Aramaic) in Petah Tikva. Other plants founded at this time include Zori ("Health" in Hebrew) in Tel Aviv and Teva ("Nature" in Hebrew) in Jerusalem. 


With the founding of the State of Israel, the local drug market expanded rapidly. While most pharmaceutical manufacturing companies were privately owned, Teva began trading on the Tel Aviv Stock Exchange in 1951. In 1964, Assia and Zori merged and acquired a controlling interest in Teva. A period of consolidation in the Israeli pharmaceutical industry beginning in the 1960s culminated with the 1976 union of Teva, Assia, and Zori to create Israel’s largest drugmaker, Teva Pharmaceutical Industries Ltd. 

In 1984 the U.S. passed the Hatch-Waxman Act, enabling Teva’s entry into generic medicines in America. Through a 50-50 joint venture with W.R. Grace, Teva formed TAG Pharmaceuticals in 1985. The joint company acquired Lemmon in Sellersville, Pennsylvania, facilitating Teva’s entry into the U.S. market. In 1987, Teva began trading on the NASDAQ. The company became full owner of TAG Pharmaceuticals in 1992. Together with Lemmon, this consolidation created Teva Pharmaceutical USA Inc. By the year 2000, through a series of acquisitions, Teva became the largest generic pharmaceutical company in North America. Teva began trading on the NYSE in 2012.


Today Teva has a portfolio of more than 1,000 molecules, producing approximately 64 billion tablets and capsules a year at 66 manufacturing facilities. The company ranks among the 10 top pharmaceutical companies internationally and is active in 60 countries. Approximately 45,000 employees around the world are dedicated to Teva's mission of increasing access to high-quality healthcare for people everywhere at every stage of life.


Company website:

bottom of page